Dr. Choueiri highlights new adjuvant pembrolizumab findings in high-risk renal cell carcinoma
June 3rd 2022The new findings, “further support the use of adjuvant pembrolizumab after nephrectomy as a standard of care in patients with localized renal cell carcinoma at increased risk for recurrence,” says Toni K. Choueiri, MD.
Dr. Kibel discusses TRUS-guided and transperineal prostate biopsy
June 2nd 2022"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.
Destigmatizing Urology: Dr. Leibovich discusses testicular cancer
May 27th 2022“A lot of people that are fatigued [and] a lot of people that have back pain assume it's something else, and we have the same masculinity concerns or embarrassment concerns about reporting gynecomastia. So, all these things feed into a potential in delaying diagnosis,” says Bradley C. Leibovich, MD, FACS.
Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer
May 25th 2022"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.
Destigmatizing Urology: Dr. Pruthi discusses mental health
May 23rd 2022“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.
Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma
May 20th 2022In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.
Elevated FSH is associated with decline in sperm concentration
May 20th 2022“We found that men with an elevated FSH but a normal semen test were more likely to have a decline in their sperm concentration and their total motile sperm count over time…when compared to men also starting with the normal semen test but with a normal FSH,” says Joshua Halpern, MD.
Sipuleucel-T: An innovative immunotherapy option for metastatic castration-resistant prostate cancer
May 19th 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).
Dr. Murray on real-world study of antegrade administration of reverse thermal mitomycin gel for UTUC
May 16th 2022Katie Murray, DO, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube.